PARTICIPANT LIST Raymond Lobins, DO | David Potter, MD | Mark Karwal, MD | Shahid Waheed, MD | Somasekhara R. Bandi, MD | Christiane Zoghbi, MD | Hilary Ufearo, MBBS
2024
Biomarker could improve prediction of response to immunotherapy in melanoma
If melanoma spreads, there are various therapies that can be used. However, there is still insufficient research into who responds to which therapy and whether resistance may develop over time.
Patient Preference Plays Limited Role in Selection of Therapy for Melanoma
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants whether factors such as patient preference influence their choice of melanoma treatment in the second article of a 2-part series.
Clinical trials pilot program a gamechanger for regional patients
If it weren’t for clinical trials, Gippsland’s Steve Wadey says he wouldn’t be alive today.